{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:42:09Z","timestamp":1790181729685,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Eastern Europe and Central Asia (EECA) is one of the regions where the HIV epidemic continues to grow at a concerning rate. Antiretroviral therapy (ART) coverage in EECA countries has significantly increased during the last decade, which can lead to an increase in the risk of emergence, transmission, and spread of HIV variants with drug resistance (DR) that cannot be controlled. Because HIV genotyping cannot be performed in these countries, data about HIV DR are limited or unavailable.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>To monitor circulating HIV-1 genetic variants, assess the prevalence of HIV DR among patients starting antiretroviral therapy, and reveal potential transmission clusters among patients in six EECA countries: Armenia, Azerbaijan, Belarus, Russia, Tajikistan, and Uzbekistan.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>We analyzed 1071 HIV-1 pol-gene fragment sequences (2253\u20133369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019. HIV Pretreatment DR (PDR) and drug resistance mutation (DRM) prevalence was estimated using the Stanford HIV Resistance Database. The PDR level was interpreted according to the WHO standard PDR survey protocols. HIV-1 subtypes were determined using the Stanford HIV Resistance Database and subsequently confirmed by phylogenetic analysis. Transmission clusters were determined using Cluster Picker.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Analyses of HIV subtypes showed that EECA, in general, has the same HIV genetic variants of sub-subtype A6, CRF63_02A1, and subtype B, with different frequencies and representation for each country.<\/jats:p>\n<jats:p>The prevalence of PDR to any drug class was 2.8% in Uzbekistan, 4.2% in Azerbaijan, 4.5% in Russia, 9.2% in Armenia, 13.9% in Belarus, and 16.7% in Tajikistan. PDR to protease inhibitors (PIs) was not detected in any country. PDR to nucleoside reverse-transcriptase inhibitors (NRTIs) was not detected among patients in Azerbaijan, and was relatively low in other countries, with the highest prevalence in Tajikistan (5.6%). The prevalence of PDR to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) was the lowest in Uzbekistan (2.8%) and reached 11.1% and 11.4% in Tajikistan and Belarus, respectively.<\/jats:p>\n<jats:p>Genetic transmission network analyses identified 226\/1071 (21.1%) linked individuals, forming 93 transmission clusters mainly containing two or three sequences. We found that the time since HIV diagnosis in clustered patients was significantly shorter than that in unclustered patients (1.26 years vs 2.74 years). Additionally, the K103N\/S mutation was mainly observed in clustered sequences (6.2% vs 2.8%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our study demonstrated different PDR prevalence rates and DR dynamics in six EECA countries, with worrying levels of PDR in Tajikistan and Belarus, where prevalence exceeded the 10% threshold recommended by the WHO for immediate public health action.<\/jats:p>\n<jats:p>Because DR testing for clinical purposes is not common in EECA, it is currently extremely important to conduct surveillance of HIV DR in EECA due to the increased ART coverage in this region.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0257731","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T18:38:43Z","timestamp":1642790323000},"page":"e0257731","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0138","authenticated-orcid":true,"given":"Alina","family":"Kirichenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Kireev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2826-699X","authenticated-orcid":true,"given":"Alexey","family":"Lopatukhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Murzakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-1415","authenticated-orcid":true,"given":"Ilya","family":"Lapovok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-5594","authenticated-orcid":true,"given":"Daria","family":"Saleeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Ladnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agigat","family":"Gadirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Ibrahimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aygun","family":"Safarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-7444","authenticated-orcid":true,"given":"Trdat","family":"Grigoryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshak","family":"Petrosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatevik","family":"Sarhatyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gasich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Bunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Glinskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Yurovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustam","family":"Nurov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alijon","family":"Soliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laylo","family":"Ismatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkin","family":"Musabaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Kazakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visola","family":"Rakhimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Pokrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"pone.0257731.ref001","unstructured":"UNAIDS DATA, 2020. Reference. Available online: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2020_aids-data-book_en.pdf."},{"key":"pone.0257731.ref002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijid.2018.03.007","article-title":"HIV care in Central and Eastern Europe: How close are we to the target","volume":"70","author":"D Gokengin","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"8","key":"pone.0257731.ref003","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Antiretroviral Therapy Cohort Collaboration","year":"2017","journal-title":"Lancet HIV"},{"issue":"9731","key":"pone.0257731.ref004","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/S0140-6736(10)60705-2","article-title":"Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis","volume":"375","author":"D Donnell","year":"2010","journal-title":"Lancet"},{"key":"pone.0257731.ref005","doi-asserted-by":"crossref","first-page":"c2205","DOI":"10.1136\/bmj.c2205","article-title":"Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study","volume":"340","author":"J Del Romero","year":"2010","journal-title":"BMJ"},{"issue":"11","key":"pone.0257731.ref006","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/OLQ.0b013e31817e2491","article-title":"Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil.","volume":"35","author":"MG Melo","year":"2008","journal-title":"Sex Transm Dis"},{"key":"pone.0257731.ref007","unstructured":"UNAIDS DATA, 2017. Available online: https:\/\/www.unaids.org\/en\/resources\/documents\/2017\/2017_data_book."},{"issue":"5","key":"pone.0257731.ref008","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"L Wittkop","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pone.0257731.ref009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study","volume":"12","author":"RL Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"pone.0257731.ref010","article-title":"Global action plan on HIV drug resistance 2017\u20132021: 2018 progress report","author":"World Health Organization\u200e","year":"2018"},{"issue":"9","key":"pone.0257731.ref011","first-page":"1362","article-title":"Impact of HIV Drug Resistance on HIV\/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa [published correction appears in J Infect Dis. 2017 Nov 15;216(8):1048].","volume":"215","author":"AN Phillips","year":"2017","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0257731.ref012","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/cid\/ciy895","article-title":"The Clinical Implications of Pretreatment Drug Resistance-A Moving Target","volume":"69","author":"RW Shafer","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0257731.ref013","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe","volume":"62","author":"LM Hofstra","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"pone.0257731.ref014","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/infdis\/jit111","article-title":"Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings","volume":"207","author":"V Cambiano","year":"2013","journal-title":"J Infect Dis"},{"key":"pone.0257731.ref015","author":"World Health Organization","year":"2015","journal-title":"HIV Drug Resistance Surveillance Guidance\u20142015 Update"},{"key":"pone.0257731.ref016","author":"World Health Organization","year":"2017","journal-title":"Guidelines on the public health response to pretreatment HIV drug resistance"},{"key":"pone.0257731.ref017","article-title":"Surveillance of HIV Drug Resistance in Adults Initiating Antiretroviral Therapy (Pre-treatment HIV Drug Resistance).","author":"World Health Organization","year":"2014"},{"issue":"4","key":"pone.0257731.ref018","first-page":"34","article-title":"Analysis of HIV subtypes and drug resistant variants circulating in Saint Petersburg. HIV Infect.","volume":"3","author":"NYe Dement\u2019eva","year":"2011","journal-title":"Immunosuppressive Disord"},{"issue":"43","key":"pone.0257731.ref019","first-page":"148","article-title":"Analysis of the prevalence of primary resistance of HIV to antiretroviral drugs in the Volga Federal District","volume":"3","author":"NN Zaytseva","year":"2016","journal-title":"Medical almanac"},{"issue":"2","key":"pone.0257731.ref020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.22328\/2077-9828-2019-11-2-75-83","article-title":"Prevalence and structure of HIV-1 drug resistance among treatment naive patients since the introduction of antiretroviral therapy in the Russian Federation. HIV Infect","volume":"11","author":"AA Kirichenko","year":"2019","journal-title":"Immunosuppressive Disord"},{"issue":"1","key":"pone.0257731.ref021","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/aid.2020.0096","article-title":"Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan","volume":"37","author":"A Mamatkulov","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"pone.0257731.ref022","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1570162X13666150407142834","article-title":"HIV Type 1 Subtype A1 Dominates in Armenia.","volume":"13","author":"V Laga","year":"2015","journal-title":"Current HIV research"},{"key":"pone.0257731.ref023","unstructured":"Reference of HIV-infection in Russian Federation on 31.12.2019. Available online: http:\/\/www.hivrussia.info\/wp-content\/uploads\/2020\/02\/VICH-infektsiya-v-Rossijskoj-Federatsii-na-31.12.2019.pdf."},{"key":"pone.0257731.ref024","unstructured":"Recommendations for treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection in Russian Federation, 2019. Available online: http:\/\/www.hivrussia.info\/wp-content\/uploads\/2019\/12\/Rekomendatsii-po-lecheniyu-VICH-infektsii-i-svyazannyh-s-nej-zabolevanijhimioprofilaktike-zarazheniya-VICH.pdf."},{"key":"pone.0257731.ref025","unstructured":"Monitoring procurement of drugs for HIV and HCV treatment; developing solutions to optimize the situation in order to facilitate uninterrupted access to drugs in the Republic of Armenia, 2018-2019.Available online: https:\/\/itpcru.org\/2019\/11\/12\/rezultaty-monitoringa-zakupok-preparatov-dlya-lecheniya-vich-infekczii-i-gepatita-s-v-armenii-v-2018-godu\/."},{"key":"pone.0257731.ref026","unstructured":"Clinical Guidelines: Adult and Adolescent ARV in Azerbaijan HIV, 2013. Available online: https:\/\/isim.az\/upload\/File\/reports\/ART-terapiay.pdf."},{"key":"pone.0257731.ref027","article-title":"Diagnostics and treatment patients with HIV infection","author":"Clinical Guidelines","year":"2017"},{"key":"pone.0257731.ref028","unstructured":"Analysis of national HIV treatment guidelines in 8 countries of Eastern Europe and Central Asia and 5 countries of Southeast Europe, 2020. Available online: https:\/\/network.org.ua\/wp-content\/uploads\/2020\/11\/23.09_Analyz-natsyonalnyh-protokolov-lechenyya-VYCH-ynfektsyy.pdf."},{"key":"pone.0257731.ref029","unstructured":"National Clinical guidelines of the Republic of Tajikistan \"Screening and antiretroviral therapy in adults and adolescents\", 2015. Available online: https:\/\/itpcru.org\/2015\/09\/17\/13490\/."},{"key":"pone.0257731.ref030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2105-14-317","article-title":"UK HIV Drug Resistance Database. Automated analysis of phylogenetic clusters.","volume":"14","author":"M Ragonnet-Cronin","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"pone.0257731.ref031","author":"World Health Organization","year":"2016","journal-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach"},{"key":"pone.0257731.ref032","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.meegid.2016.10.018","article-title":"Primate immunodeficiency virus classification and nomenclature: Review","volume":"46","author":"BT Foley","year":"2016","journal-title":"Infect Genet Evol"},{"issue":"4","key":"pone.0257731.ref033","first-page":"204","article-title":"Current status of HIV-1 diversity and drug resistance monitoring in the former USSR","volume":"15","author":"M. Bobkova","year":"2013","journal-title":"AIDS Rev"},{"issue":"5","key":"pone.0257731.ref034","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/aid.2017.0233","article-title":"Spatiotemporal Characteristics of the HIV-1 CRF02_AG\/CRF63_02A1 Epidemic in Russia and Central Asia","volume":"34","author":"EG Kostaki","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"15","key":"pone.0257731.ref035","first-page":"1590","article-title":"The challenge of HIV-1 subtype diversity [published correction appears in N Engl J Med. 2008 Oct 30;359(18):1972] [published correction appears in N Engl J Med. 2008 Oct 30;359(18):1965\u20136]","volume":"358","author":"BS Taylor","year":"2008","journal-title":"N Engl J Med"},{"key":"pone.0257731.ref036","author":"World Health Organization","year":"2017","journal-title":"HIV drug resistance report 2017"},{"key":"pone.0257731.ref037","author":"World Health Organization","year":"2016","journal-title":"Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations"},{"issue":"4","key":"pone.0257731.ref038","first-page":"44","article-title":"Natural polymorphisms of HIV-1 IDU-A variant pol gene","volume":"4","author":"EV Kazennova","year":"2012","journal-title":"HIV Infect. Immunosuppressive Disord"},{"key":"pone.0257731.ref039","article-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV","author":"World Health Organization","year":"2018"},{"key":"pone.0257731.ref040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eclinm.2019.03.006","article-title":"Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000\u20132016: A Pooled Sequence Analysis","volume":"9","author":"B Chimukangara","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"3","key":"pone.0257731.ref041","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/jac\/dkz502","article-title":"Pretreatment HIV drug resistance spread within transmission clusters in Mexico City","volume":"75","author":"M Mat\u00edas-Florentino","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pone.0257731.ref042","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/JVI.02579-07","article-title":"Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection","volume":"82","author":"SJ Little","year":"2008","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0340124","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T18:39:23Z","timestamp":1642790363000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257731"}},"subtitle":[],"editor":[{"given":"Jason T.","family":"Blackard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0257731","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}